Mycophenolate mofftil (MMF) as a first line agent in the treatment of the glomerular tip lesion of focal segmental glomerulosclerosis (FSGS)

被引：0

作者：

Varvarelis, Nicholas ^{[1
]}

Snyder, Richard ^{[1
]}

机构：

[1] Lehigh Valley Hosp Hlth Network, Allentown, PA USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2008年 / 51卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

263

引用

页码：A93 / A93

页数：1

共 50 条

[1] Glomerular tip lesion (GTL): Clinical features, response to corticosteroids and comparison to focal segmental glomerulosclerosis (FSGS).
HoganMoulton, AE
Hogan, SL
Falk, RJ
Jennette, JC
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A0418 - A0418
[2] Increased body weight and increased glomerular size are associated with focal segmental glomerulosclerosis (FSGS) but not with glomerular tip lesion (GTL).
Taylor, JG
Hogan, S
Falk, RJ
Jennette, JC
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A2502 - A2502
[3] GLOMERULAR TIP LESION (GTL) IS NOT ONLY STRUCTURALLY BUT ALSO CLINICALLY DISTINCT FROM OTHER TYPES OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
MILLING, DM
IWILKMAN, AS
FALK, RJ
JENNETTE, JC
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 837 - 837
[4] Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion
Howie, AJ
Pankhurst, T
Sarioglu, S
Turhan, N
Adu, D
KIDNEY INTERNATIONAL, 2005, 67 (03) : 987 - 1001
[5] Tip Lesion Variant of Focal and Segmental Glomerulosclerosis (FSGS): A Case Report in a Patient with COVID-19
Afonso, Rita S.
Cabrita, Ana
Silva, Ana P.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 91 - 91
[6] The role of plasmapheresis in the treatment of focal segmental glomerulosclerosis (FSGS)
Rao, PS
Bakir, AA
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2000, 23 (12): : 798 - 801
[7] Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis
Cattran, DC
Wang, MM
Appel, G
Matalon, A
Briggs, W
CLINICAL NEPHROLOGY, 2004, 62 (06) : 405 - 411
[8] Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib
Martin Sedlacek
Jason R. Pettus
CEN Case Reports, 2022, 11 : 225 - 230
[9] Complete remission of tip lesion variant focal segmental glomerulosclerosis (FSGS) with the Janus Kinase (JAK) inhibitor tofacitinib
Sedlacek, Martin
Pettus, Jason R.
CEN CASE REPORTS, 2022, 11 (02) : 225 - 230
[10] PembrolizumabFocal segmental glomerulosclerosis glomerular tip lesion: case report
Reactions Weekly, 2020, 1805 (1) : 242 - 242

← 1 2 3 4 5 →